Exagen (XGN) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Exagen (XGN) has outperformed YD Bio (YDES) over the past year, losing 24.3% versus a loss of 67.3%. YD Bio is the larger company by market cap ($410.1 million vs $197.9 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XGN | YDES |
|---|---|---|
| Share price | $8.17 | $5.79 |
| Market cap | $197.92M | $410.11M |
| 1-day change | -1.57% | -1.53% |
| YTD return | +36.51% | -51.76% |
| 1-year return | -24.27% | -67.33% |
| 5-year return | -34.28% | — |
| EPS (TTM) | $-0.81 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.23 | $22.00 |
| 52-week low | $2.59 | $1.70 |
| Distance from 52-week high | -33.20% | -73.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +24.11% | — |
| Average volume | 328.42K | 283.39K |
| Shares outstanding | 24.23M | 70.83M |
| Employees | 216 | 13 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YD Bio is about 2.1 times larger than Exagen by market value ($410.11M vs $197.92M).
- XGN has outperformed YDES by 43.1 percentage points over the past year.
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
XGN vs YDES FAQ
Which is bigger, Exagen or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $410.11M compared with $197.92M for Exagen (XGN).
Which stock has performed better over the past year, XGN or YDES?
XGN returned -24.27% over the past 12 months, compared with -67.33% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Exagen and YD Bio in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.